Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase EARLY_PHASE1 1Phase 3 1Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gynecologic 1Gastrointestinal 1

Conditions

Breast Neoplasms 15Glioblastoma 14Neoplasms 12Brain Neoplasms 12Melanoma 11Pancreatic Neoplasms 10Head and Neck Neoplasms 10Carcinoma, Non-Small-Cell Lung 10Lung Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Prostatic Neoplasms 8Glioma 8Ovarian Neoplasms 7Neoplasm Metastasis 7Lymphoma 6Colonic Neoplasms 6Multiple Myeloma 5Carcinoma, Hepatocellular 5Urinary Bladder Neoplasms 4Sarcoma 4Rectal Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, T-Cell 4Lymphoma, Large B-Cell, Diffuse 4Hodgkin Disease 4Stomach Neoplasms 3Recurrence 3Lymphoma, Non-Hodgkin 3Lymphoma, Mantle-Cell 3Leukemia, Myeloid, Acute 3

Interventions

amatuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Terminated × Carcinoma, Pancreatic Ductal × Clear all
NCT01413451 2019-12-17

Amatuximab for High Mesothelin Cancers

National Institutes of Health Clinical Center (CC)

Phase EARLY_PHASE1 Terminated
7 enrolled
GastrointestinalGynecologicOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡